Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence

A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus

(2014) D. M. Carragher et al.   JOURNAL OF IMMUNOLOGY

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine

(2012) Teresa Lambe et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Recombinant protein vaccines produced in insect cells

(2012) Manon M.J. Cox   VACCINE

Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins

(2012) Katherine A. Richards et al.   VACCINE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Adjuvants in influenza vaccines

(2012) Kohhei Tetsutani et al.   VACCINE

Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus

(2011) Mark W. LaMere et al.   JOURNAL OF IMMUNOLOGY

Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance

(2011) M. W. LaMere et al.   JOURNAL OF VIROLOGY

Influenza A viruses: new research developments

(2011) Rafael A. Medina et al.   NATURE REVIEWS MICROBIOLOGY

Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells

(2011) M. K. L. MacLeod et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein

(2010) Lina Guo et al.   ARCHIVES OF VIROLOGY

Immune mechanisms of protection: can adjuvants rise to the challenge?

(2010) Amy S McKee et al.   BMC BIOLOGY

Lack of Original Antigenic Sin in Recall CD8+ T Cell Responses

(2010) D. Zehn et al.   JOURNAL OF IMMUNOLOGY

Cytotoxic T Cells Are the Predominant Players Providing Cross-Protective Immunity Induced by  -Irradiated Influenza A Viruses

(2010) Y. Furuya et al.   JOURNAL OF VIROLOGY

PB2 Residue 158 Is a Pathogenic Determinant of Pandemic H1N1 and H5 Influenza A Viruses in Mice

(2010) B. Zhou et al.   JOURNAL OF VIROLOGY

Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses

(2010) Graeme E. Price et al.   PLoS One

Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

(2010) C.-J. Wei et al.   SCIENCE

Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines

(2010) Kanyarat Thueng-in et al.   VACCINE

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments

(2009) Michael Schotsaert et al.   Expert Review of Vaccines

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes

(2009) Lorena E Brown et al.   IMMUNOLOGY AND CELL BIOLOGY

Duration of Protection Provided by Live Attenuated Influenza Vaccine in Children

(2009) Christopher S. Ambrose et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998–2004

(2008) R. Sebastian et al.   VACCINE